Worldwide Clinical Trials, a leading global contract research organization (CRO), has finalized its acquisition of Catalyst Clinical Research, a specialized oncology CRO and scalable functional service provider (FSP).
Financial terms of the acquisition were not disclosed.
The deal expands Worldwide’s workforce to roughly 4,400 employees across more than 70 countries and strengthens its capabilities in oncology, biometrics, and FSP services.
The integration of Catalyst’s early-phase oncology expertise and robust FSP model enhances Worldwide’s scientific depth and operational agility, extending its reach across neuroscience, oncology, rare disease, and internal medicine.
Biopharma customers now gain access to a broader suite of services, advanced technology platforms, and an expanded global site network, enabling more efficient, flexible, and transparent clinical trial operations.
“The acquisition of Catalyst strengthens Worldwide’s capabilities in a very deliberate way, building a stronger, more capable CRO partner for our customers,” said Alistair Macdonald, Chief Executive Officer of Worldwide.
“It expands our reach into earlier phase oncology, adds targeted FSP and biometrics capabilities, and accelerates our technology platforms, allowing us to better support customers across the full development lifecycle with greater speed, flexibility, and transparency.”
“The completion of the Catalyst acquisition deepens Worldwide’s oncology offering and global reach,” said Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner of Kohlberg, the majority owner of the Company.
“Catalyst’s expertise, technology, and strong biotech relationships are a natural fit for Worldwide and reinforce our strategy to build a differentiated, technology-enabled CRO.”
Nik Morton, former President and CEO of Catalyst, joins Worldwide as EVP, Chief Strategy & Transformation Officer.
“Joining the Worldwide team is an exciting next chapter for Catalyst,” Morton said. “We are energized by the cultural alignment between our teams and share a deep commitment to scientific excellence, operational integrity, and a people-first approach. Together, we are well positioned to deliver even greater value to customers worldwide.”
Catalyst’s Chairman of the Board, Nick Dyer, also joins Worldwide’s Board of Directors. An integration team has been established, with a comprehensive plan underway to ensure a smooth transition for employees, customers, and partners. Worldwide will leverage combined strengths to unlock new growth and innovation opportunities for its clients.
